The European Medicines Agency recognized severe allergic responses as a possible adverse effect of Novavax Inc’s (NVAX.O) COVID-19 vaccination on Thursday.

The vaccine was approved by US authorities on Wednesday, and its product label in the US advises against giving the injection to those who have a history of adverse reactions to any of the shot’s components. more info

The EMA also said that it will revise the vaccine’s product labeling to include unusual or diminished skin sensation as a new adverse effect.

According to the European Centre for Disease Prevention and Control, just 250,000 doses of Novavax’s COVID vaccination, Nuvaxovid, have been delivered in Europe since its debut in December.

Source: Reuters

LEAVE A REPLY

Please enter your comment!
Please enter your name here